

Substitute for form 1449/PTO
(Revised 04/2003)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/035,420
Filing Date October 25, 2001
First Named Inventor Wolfe
Group Art Unit 1644
Examiner Name Not yet assigned
Attorney Docket Number PP16022.004 (035784/240411)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
Ar	31	EP 0 360 937	04-04-1990	Cetus Corporation		
	32	WO 98/27211	06-25-1998	Universidade Federal De Minas Gerais		
	33	WO 02/080976	10-17-2002	Chiron Corporation		

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
Ar	34	LEE, J.K., et al., "Purification of Human Interferon- β from Recombinant <i>E. coli</i> ," <i>Korean Biochemical Journal</i> , 1990, pp. 166-171, Vol. 23(2).	
	35	PEPINSKY, R.B., "Selective Precipitation of Proteins from Guanidine Hydrochloride-Containing Solutions with Ethanol," <i>Analytical Biochemistry</i> , 1991, pp. 177-181, Vol. 195.	
	36	RUSSELL-HARDE, D., et al., "The Use of Zwittergent 3-14 in the Purification of Recombinant Human Interferon- β Ser ¹⁷ (Betaseron)," <i>Journal of Interferon and Cytokine Research</i> , 1995, pp. 31-37, Vol. 15(1).	
	37	VAN OSS, C.J., "On the Mechanism of the Cold Ethanol Precipitation Method of Plasma Protein Fractionation," <i>Journal of Protein Chemistry</i> , 1989, pp. 661-668, Vol. 8(5).	


Examiner
Signature

[Signature]

Date
Considered

2-18-03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FOR FORM 1449/PTO (Revised 04/2003) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		O I P E U C JUN 26 2003		Complete if Known	
		Application Number		10/035,420	
		Filing Date		October 25, 2001	
		First Named Inventor		Wolfe	
		Group Art Unit		1644	
Examiner Name		Not yet assigned			
Attorney Docket Number		PP16022.004 (035784/240411)			
U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A	38	EP 0 215 658 B1	06-01-1994	Cetus Oncology Corporation	
OTHER DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			English Language Translation Attached
Examiner Signature				Date Considered	2.18.03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JUN 30 2003
TECH CENTER 1600/2900

Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number 10/035,420
Filing Date October 25, 2001
First Named Inventor Wolfe
Group Art Unit 1644
Examiner Name Not yet assigned
Attorney Docket Number PP16022.004 (35784/2404198)

RECEIVED
JUL 25 2002
TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
AK ↓ V	1	US-4,462,940	07-31-1984	Hanisch <i>et al.</i>	
	2	US-4,816,440	03-28-1989	Thomson, J.W.	
	3	US-4,894,330	01-16-1990	Hersheson <i>et al.</i>	
	4	US-4,931,543	06-05-1990	Halenbeck <i>et al.</i>	
	5	US-4,992,271	02-12-1991	Fernandes <i>et al.</i>	
	6	US-5,162,507	11-10-1992	Wolfe <i>et al.</i>	
	7	US-5,643,566	07-01-1997	Hanisch <i>et al.</i>	
	8	US-5,702,699	12-30-1997	Hanisch <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
AK ↓ V	9	WO 95/31479	11-23-1995	Inhale Therapeutic Systems, Inc.		
	10	EP 0 217 645 B1	04-08-1987	Cetus Corporation		
	11	EP 0 270 799 B1	06-15-1988	Cetus Oncology Corporation		

Examiner
Signature

[Handwritten Signature]

Date
Considered

2.18.04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO
(Revised 10/2001)

Complete if Known

Application Number	10/035,420
Filing Date	October 25, 2001
First Named Inventor	Wolfe
Group Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	PP16022.004 (35784/24049)


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
[Signature]	12	AHN, J., et al., "Investigation of Refolding Condition for Pseudomonas Fluorescens Lipase by Response Surface Methodology," <i>J. Biotechnol.</i> , 1997, pp. 151-160, Vol. 54(3).	.
	13	BAM, N., et al., "Molten Globule Intermediate of Recombinant Human Growth Hormone: Stabilization with Surfactants," <i>Biotechnol. Prog.</i> , 1996, pp. 801-809, Vol. 12(6).	.
	14	CARPENTER, J., and J.H. CROWE, "The Mechanism of Cryoprotection of Proteins by Solutes," <i>Cryobiology</i> , 1988, pp. 244-255, Vol. 25(3).	.
	15	CHARMAN, S., et al., "Techniques for Assessing the Effects of Pharmaceutical Excipients on the Aggregation of Porcine Growth Hormone," <i>Pharm. Res.</i> , 1993, pp. 954-962, Vol. 10(7).	.
	16	CLELAND, J., et al., "Polyethylene Glycol Enhanced Protein Refolding," <i>Biotechnology</i> , 1992, pp. 1013-1019, Vol. 10(9).	.
	17	DAUGHERTY, D., et al., "Artificial Chaperone-Assisted Refolding of Citrate Synthase," <i>J. Biol. Chem.</i> , 1998, pp. 33961-33971, Vol. 273(51).	.
	18	DRYDEN, D., and M.P. WEIR, "Evidence for an Acid-Induced Molten-Globule State in Interleukin-2; A Fluorescence and Circular Dichroism Study," <i>Biochim. Biophys. Acta</i> , 1991, pp. 94-100, Vol. 1078(1).	.
	19	EDY, V., et al., "Stabilisation of Mouse and Human Interferons by Acid pH Against Inactivation Due to Shaking and Guanidine Hydrochloride," <i>Proc. Soc. Exp. Biol. Med.</i> , 1974, pp. 249-253, Vol. 146(1).	.
	20	EDY, V., et al., "Stable and Unstable Forms of Human Fibroblast Interferon," <i>Infect. Immun.</i> , 1977, pp. 445-448, Vol. 16(2).	.
	21	GAUTHIER, M., and P. A. PATSTON, "Reactivation of C1-Inhibitor Polymers by Denaturation and Gel-Filtration Chromatography," <i>Anal. Biochem.</i> , 1997, pp. 228-233, Vol. 248(2).	.
[Signature]	22	HOURY, W., et al., "The Nature of the Initial Step in the Conformational Folding of Disulphide-Intact Ribonuclease A," <i>Nat. Struct. Biol.</i> , 1995, pp. 495-503, Vol. 2(6).	.
	23	JARIWALLA, R., et al., "The Reactivation of Human Interferons by Guanidine Thiocyanate," <i>Experientia</i> , 1980, pp. 1390-1391, Vol. 36(12).	.
	24	KENDRICK, B., et al., "Quantitation of the Area of Overlap Between Second-Derivative Amide I Infrared Spectra to Determine the Structural Similarity of a Protein in Different States," <i>J. Pharm. Sci.</i> , 1996, pp. 155-158, Vol. 85(2).	.
	25	MUZAMMIL, S., et al., "Molten Globule-Like State of Human Serum Albumin at Low pH," <i>Eur. J. Biochem.</i> , 1999, pp. 26-32, Vol. 266(1).	.



Substitute for form 1449B/PTO (Revised 10/2001)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/035,420
		Filing Date	October 25, 2001
		First Named Inventor	Wolfe
		Group Art Unit	1644
		Examiner Name	Not yet assigned
Sheet	3 of 3	Attorney Docket Number	PP16022.004 (35784/240411)
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
26	ROZEMA, D., and S. H. GELLMAN, "Artificial Chaperone-Assisted Refolding of Denatured-Reduced Lysozyme: Modulation of the Competition Between Renaturation and Aggregation," <i>Biochemistry</i> , 1996, pp. 15760-15771, Vol. 35(49).		
27	ROZEMA, D., and S. H. GELLMAN, "Artificial Chaperone-Assisted Refolding of Carbonic Anhydrase B," <i>J. Biol. Chem.</i> , 1996, pp. 3478-3487, Vol. 271(7).		
28	TODHUNTER, R., <i>et al.</i> , "Structure of Equine Type I and Type II Collagens," <i>Am. J. Vet. Res.</i> , 1994, pp. 425-431, Vol. 55(3).		
29	WEIR, M., <i>et al.</i> , "Micropreparative Purification of Recombinant Human Interleukin-2," <i>J. Chromatogr.</i> , 1987, pp. 209-215, Vol. 396.		
30	XIE, Y. and D. B. WETLAUFER, "Control of Aggregation in Protein Refolding: The Temperature-Leap Tactic," <i>Protein Sci.</i> , 1996, pp. 517-523, Vol. 5(3).		

Examiner Signature	<i>[Signature]</i>	Date Considered	2-18-04
--------------------	--------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Information Disclosure Statement by Applicant				Complete if Known		
Substitute for form 1449/PTO (Revised 04/2003)				Application Number	10/035,420	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	October 25, 2001	
				First Named Inventor	Wolfe	
				Group Art Unit	1644	
				Examiner Name	Not yet assigned	
Sheet	1	of	1	Attorney Docket Number	PP16022.004 (035784/240411)	
U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
W	39	KR 9 306 706 B	07-23-1993	Lucky Ltd.		
OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
Examiner Signature				Date Considered	2-18-04	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.